Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
The Hindu — Health · 16 Sep 2026
We couldn't retrieve the full article from The Hindu — Health, so this is the available summary.
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
Related articles
India · The Hindu — Health · 7 hours agoMexico bans cellphones in schools, despite opposition from parents worried about violence
Mexican authorities are also preparing to implement regulations this month that will require digital platforms to remove posts containing hate speech, abuse, sexual violence,…
Read full article
India · The Hindu — Health · 7 hours agoApproval of India-made version of HIV-prevention shot raises hopes in low-income countries
Generic lenacapavir should start to become available in some places within weeks
Read full article
India · The Hindu — Health · 7 hours agoWHO urged to review drinking water standards amid nitrate health fears
Surface water models indicate that hundreds of millions of people globally are exposed to elevated nitrate levels, the letter warned
Read full article